Peter Thiel (Riccardo Savi/Sipa via AP Images)

Pe­ter Thiel joins fund­ing round for pep­tide drug play­er in lat­est swing at emerg­ing biotech mar­ket

For ven­ture cap­i­tal­ists work­ing in ear­ly-stage biotech, fail­ures are more com­mon than vic­to­ries as in­vestors search for nov­el path­ways to treat well-trod­den ther­a­peu­tic ar­eas. For the big-name in­vestors, that’s equal­ly true — but if your name’s Pe­ter Thiel, a cer­tain grav­i­ty and high ex­pec­ta­tions come with your mon­ey.

Bil­lion­aire tech en­tre­pre­neur and Face­book co-founder Thiel has joined a $35.4 mil­lion Se­ries B round for Pep­ti­log­ics, a pep­tide drug de­sign and de­vel­op­ment biotech, as the com­pa­ny looks to ex­pand on its lead an­ti-in­fec­tive can­di­date and tar­get more drugs for mar­ket.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA